SCHEMBL5550142

SCHEMBL5550142

COC(=O)c1cncc2sc(Oc3ccccc3-c3ccccc3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK1D P48730 4/20 0.46
▸ GSK3A P49840 4/20 0.46
▸ GSK3B P49841 4/20 0.46
▸ DYRK1A Q13627 4/20 0.46
▸ AURKB Q96GD4 4/20 0.46
▸ PLK4 O00444 3/20 0.46
▸ AURKA O14965 3/20 0.46
▸ DAPK3 O43293 3/20 0.46
▸ CHEK2 O96017 3/20 0.46
▸ CDK1 P06493 3/20 0.46
▸ PIM1 P11309 3/20 0.46
▸ CDK2 P24941 3/20 0.46
▸ MAPK9 P45984 3/20 0.46
▸ CSNK2A1 P68400 3/20 0.46
▸ PLK3 Q9H4B4 3/20 0.46
▸ PIM2 Q9P1W9 3/20 0.46
▸ PRKACA P17612 2/20 0.46
▸ RPS6KA3 P51812 2/20 0.46
▸ SGK2 Q9HBY8 2/20 0.46
▸ MAP3K8 P41279 6/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5550139 0.79 CCNC (0.61) CSNK1DGSK3AGSK3BDYRK1AAURKB
SCHEMBL11421575 0.73 SLC6A3 (0.59) FGFR1FGFR3KMT2AMEN1ALDH1A1
SCHEMBL7060310 0.72 GSK3A (0.78) CSNK1DGSK3AGSK3BDYRK1AAURKB
SCHEMBL24499494 0.68 PDCD1 (0.50) FGFR1FGFR3MAPK1KMT2AMEN1
SCHEMBL30205037 0.67 LMNA (0.49) FGFR1FGFR3MAPK1KMT2AMEN1
SCHEMBL7053352 0.67 CSNK1D (0.53) CSNK1DGSK3AGSK3BDYRK1AAURKB
SCHEMBL24499499 0.67 ALDH1A1 (0.48) FGFR1FGFR3MAPK1KMT2AMEN1
SCHEMBL29598166 0.67 ALDH1A1 (0.48) FGFR1FGFR3MAPK1KMT2AMEN1
SCHEMBL6927417 0.66 FGFR1 (0.58) FGFR1FGFR3MAPK1CCNCCDK8
SCHEMBL5550119 0.66 ICAM1 (0.55) CSNK1DGSK3AGSK3BDYRK1AAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1753428-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS Abbott Laboratories (US) 2007-02-21 — — EP disclosed
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABBOTT LABORATORIES 2006-04-06 — — US disclosed
WO-2005110410-A2 KINASE INHIBITORS AS THERAPEUTIC AGENTS ABBOTT LABORATORIES (US) 2005-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074102-A1 Kinase inhibitors as therapeutic agents ABL1, MAP3K19, MAP3K20 CSNK1D 151/4885GSK3A 453/4885GSK3B 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback